Arthritis, Psoriatic
91
13
20
54
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
29 trials with published results (32%)
Research Maturity
54 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.6%
6 terminated out of 91 trials
90.0%
+3.4% vs benchmark
33%
30 trials in Phase 3/4
54%
29 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 54 completed trials
Clinical Trials (91)
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
A Long-term Extension Study of Ustekinumab in Pediatric Participants
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
Pain in Inflammatory Joint Diseases
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis